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A non-internalizing αvβ3 integrin ligand was conjugated to the 
anticancer drug MMAE through a β-glucuronidase-responsive 
linker. In the presence of β-glucuronidase, only the conjugate 
bearing a PEG4 spacer inhibited the proliferation of integrin-
expressing cancer cells at low nanomolar concentrations, 
indicating important structural requirements for the efficacy of 
these therapeutics. 
Among the current pharmacological approaches for cancer 
treatment, cytotoxic agents are still frequently administered to 
patients with early-stage or advanced disease, as single agents 
or in combination with radiation, before or after surgery.
1
 The 
covalent conjugation of these drugs to specific ligands 
(antibodies, peptides or small molecules) capable of selective 
binding to tumour-overexpressed receptors, has been 
proposed as a suitable strategy to increase the tumour 
accumulation of these therapeutics, sparing healthy tissues 
and reducing dose-limiting toxicities.
2 
In particular, the so-
called Antibody-Drug Conjugates (ADCs)
3 
 and Small Molecule-
Drug Conjugates (SMDCs)
4 
 consist of a targeting unit and a 
cytotoxic payload covalently assembled through a linker, which 
should be perfectly stable in plasma and be cleaved at the 
tumour site. It has been originally postulated that, in order to 
minimize side-toxicity in healthy cells, the payload should be 
preferentially released within the intracellular compartments 
(e.g. lysosomes) of the targeted cancer cell, upon receptor-
mediated endocytosis of the conjugate. More recently, the 
observation of the high mutation rates of cancer cells (which 
may generate different cell populations, showing different 
levels of antigen expression and drug resistance)
5
 and of the 
role on disease progression played by cancer-associated host 
cells (e.g. tumour endothelial cells,
6
 fibroblasts,
7
 infiltrating 
immune cells
8
) stimulated the hypothesis that the extracellular 
release of the drug and its diffusion within the tumour mass 
may increase the treatment efficacy.
9
 In line with these 
observations, new classes of antigens (collagen IV,
10
 fibrin,
11
 
carbonic anhydrase IX,
12
 oncofetal fibronectin
13
 and tenascin 
C
14
) have been explored as targets for non-internalizing 
conjugates and new linkers for the selective extracellular 
release of the payload have been proposed. 
Since 2012, our group has explored the conjugation of 
different anticancer drugs to the peptidomimetic compound 
cyclo(DKP-RGD)
15
 (compound 1 in Figure 1), a low-nanomolar 
ligand of integrin αvβ3.
16
 The latter is a heterodimeric 
transmembrane glycoprotein overexpressed in a variety of 
cancer types (e.g. melanoma, glioblastoma, renal cell 
carcinoma, and tumours of lung, ovary, breast, prostate, and 
colon), where it is involved in disease progression.
17
 
 
Figure 1. Molecular structure of the αvβ3 integrin ligand cyclo(DKP-RGD) (1) and the 
conjugate cyclo(DKP-RGD)-NPV-PTX (2). 
In contrast with literature reports on similar ligands,
18
 confocal 
microscopy studies recently showed that ligand 1 accumulates 
on the surface of αvβ3 integrin-expressing cancer cells, without 
promoting a significant receptor-mediated endocytosis.
19
 
While this observation may further stimulate the existing 
debate about the link between the agonist/antagonist 
behaviour and the internalization of integrin ligands,
20
 we 
focused on the development of non-internalizing conjugates 
based on ligand 1. In particular, we recently developed a new 
SMDC (compound 2 in Figure 1), in which the linker moiety 
consisted of a substrate of elastase (the Asn-Pro-Val peptide 
sequence), a serine protease released in the extracellular 
tumour environment by tumour-infiltrating neutrophils in 
response to inflammation stimuli.
19
 The resulting conjugate 
exhibited a higher antiproliferative activity against renal cell 
carcinoma cells 786-O upon addition of elastase in the cell 
medium, indicating that 2 may be therapeutically efficient 
against inflamed tumours. 
  
 
  
 
 
 
Figure 2. Molecular structures of the αvβ3 integrin-targeted conjugates 3a and 3b, featuring the cyclo(DKP-RGD) peptidomimetic as targeting unit, a glucuronide linker, the 
anticancer drug monomethyl auristatin E (MMAE) and different spacers (glutaric acid in 3a, a triazole and PEG4 spacer in 3b) between the linker and the targeting unit. The 
mechanism of MMAE release upon linker cleavage mediated by β-glucuronidase is depicted. 
Other enzymes may be suitable effectors of non-internalizing 
SMDCs. For instance, β-glucuronidase is a well-known tumour-
associated enzyme, responsible for the hydrolysis of β-D-
glucuronic acid residues in glycosaminoglycans. Despite its 
primary expression in intracellular compartments (lysosomes), 
β-glucuronidase is often abundant in tumour extracellular 
areas, shed by apoptotic or necrotic cancer cells as well as by 
tumour-infiltrating monocytes and neutrophils.
21
 For these 
reasons, β-glucuronidase-responsive linkers have been 
installed in a large variety of anticancer biotherapeutics, 
designed to release anticancer drugs both inside
22
 and 
outside
23,24
 cancer cells. 
Inspired by these studies, we designed two new integrin-
targeted conjugates (3a and 3b in Figure 2) equipped with 
ligand 1, a glucoronide linker, a self-immolative spacer and the 
potent microtubule-disruptor monometyl auristatin E (MMAE), 
the well-known payload of the marketed ADC Adcetris®. Since 
the spacer between the ligand and the linker moieties may be 
crucial for different aspects of the final SMDC assembly (e.g. to 
modulate the conjugate flexibility, solubility, ligand binding 
affinity and linker cleavage),
25
 conjugates 3a and 3b featured 
two different spacer units (a glutaric acid derivative in 
conjugate 3a and a triazole + PEG4 spacer in 3b). The non-
optimized synthetic procedures for the preparation of 
conjugates 3a,b are described in Scheme 1. Firstly, a glycosidic 
bond between bromide 4 and phenol 5 was formed, affording 
intermediate 6. Upon aldehyde reduction, the nitro group of 7 
was reduced via catalytic hydrogenation. Aniline 8 was used as 
a common intermediate for the preparation of both final 
conjugates. For the synthesis of 3a, 8 was Fmoc-protected and 
reacted with 4-nitrophenylchloroformate, affording carbonate 
9. The latter was treated with MMAE and HOBt, enabling 
carbamate bond formation with the secondary amine of the 
free drug. Basic aqueous conditions allowed protecting group 
removal, and the resulting free aniline 10 was reacted with 
di(succinimidyl) glutarate. Following a well-known procedure, 
the N-hydroxysuccinimidyl ester 11 was reacted with the 
benzylic amine of the cyclo(DKP-RGD) ligand 15
16a
 to afford 3a. 
Conjugate 3b was prepared following a similar synthetic plan. 
However, a significant improvement consisted in the 
derivatization of 8 with 4-pentynoic acid, which avoided the 
installation/removal of protecting groups at the low-reactive 
aniline moiety and the conjugation of the azide-bearing ligand 
16,
16c,f
 via a chemoselective copper-catalyzed Huisgen 
   
  
 
 
cycloaddition. The conjugates were purified by semi-
preparative HPLC, characterized by high-resolution mass 
spectrometry and lyophilized before biological analysis.  
 
 
Scheme 1. Synthesis of conjugates 3a and 3b. Reagents an conditions: a) Ag2O, molecular sieves, MeCN, overnight; b) Silica gel, NaBH4, iPrOH/CHCl3, 2.5 h; c) H2, Pd/C, EtOAc, 
EtOH, MeOH, overnight; d) Fmoc-OSu, iPr2NEt, DMAP, CH2Cl2, 3 h; e) 4-nitrophenylchloroformate, pyridine, THF, 3 h; f) MMAE, HOBt, iPr2NEt, pyridine, DMF, 2 h; g) LiOH, 1:1 
MeOH/H2O, 2 h; h) Di(succinimidyl)glutarate, iPr2NEt, DMAP, DMF, 3 h; i) 4-pentynoic acid, HATU, HOBt, iPr2NEt, DMF, overnight; j) PBS pH 7.5/DMF, 3 h; k) CuSO4·5H2O, sodium 
ascorbate, DMF/H2O. 
The affinity of conjugates 3a,b for the purified αvβ3 integrin 
receptor was estimated. The conjugates were found to inhibit 
the binding of the biotinylated vitronectin at nanomolar 
concentrations, as shown in Table 1. The IC50 values of both 
the MMAE−RGD conjugates 3a and 3b were comparable, albeit 
a bit higher, to that of the free cyclo(DKP-RGD) ligand 1. These 
data reassured us that the enormous increase of steric 
hindrance in the MMAE−RGD conjugates did not significantly 
influence the high affinity for the αvβ3 integrin receptor. 
 
Table 1. Inhibition of biotinylated vitronectin binding to the αvβ3 receptor. 
Compound αvβ3 IC50 [nM]
[a]
 
cyclo(DKP-RGD)-A-Gluc-MMAE (3a) 22.0 ± 9.6 
cyclo(DKP-RGD)-B-Gluc-MMAE (3b) 76.7 ± 5.8 
cyclo(DKP-RGD) (1)
15
 4.5 ± 1.1 
[a]: IC50 values were determined as the concentration of compound required for 50% 
inhibition of biotinylated vitronectin binding as estimated by GraphPad Prism software. 
All values are the arithmetic mean ± the standard deviation (SD) of duplicate 
determinations. 
  
  
  
 
 
Following the protocol reported by Papot and coworkers,
23
 the 
cytotoxic activity of 3a,b was examined by incubating the RGD-
MMAE conjugates with αvβ3-expressing cancer cells, in the 
presence or absence of β-glucuronidase. This experiment aims 
at simulating the tumour microenvironment in vivo, where a 
high extracellular expression of β-glucuronidase is expected to 
promote MMAE release from the non-internalizing conjugates, 
and the free drug can then enter cancer cells by passive 
diffusion. Human glioblastoma U87MG
26
 and renal cell 
carcinoma 786-O
19
 cells were chosen, and their high αvβ3 
surface expression was confirmed by flow cytometry analysis 
(Figure S1 in the Supporting Information). 
 
Figure 3. Antiproliferative activity of conjugates 3a, 3b and free MMAE in αvβ3-
expressing human glioblastoma (U87MG) and renal cell carcinoma (786-O) cells, after 
incubation for 96 hours in the absence (experiments A and C) or presence (experiments 
B and D) of β-glucuronidase. Data points are averages of 3 experiments. Error bars 
indicate SDs. Calculated IC50 values (M) are listed below each experiment. 
As shown in Figure 3A and 3C, in the absence of β-
glucuronidase, conjugates 3a,b proved poorly cytotoxic, 
whereas free MMAE inhibited cell proliferation at very low 
concentration (IC50 = ca. 86 pM against U87MG and ca. 2 nM 
against 786-O cells). Interestingly, in both cell lines the activity 
of conjugate 3b was found to be a bit higher (IC50 4.1-7.8 times 
lower) than that of analogue 3a. On the other hand, the 
anticancer activity of conjugate 3b increased dramatically 
upon enzyme addition, with IC50 values in the same low-
nanomolar range of free MMAE (Figure 3B and 3D). 
Noticeably, this enhanced cytotoxicity was not observed for 
conjugate 3a, which showed a micromolar activity regardless 
of the β-glucuronidase addition. Conceivably, the lack of 
anticancer activity of 3a can be ascribed to its structural 
features. In particular, the glutarate spacer (Spacer A in Figure 
2) establishes a suboptimal distance between the glucuronide 
linker and the bulky integrin ligand, affecting the efficiency of 
the β-glucuronidase-mediated cleavage. On the contrary, the 
triazole + PEG4 spacer (Spacer B) in conjugate 3b allows a 
perfect drug release process. Finally, in the absence of the 
extracellular enzyme, conjugate 3b inhibits the proliferation of 
αvβ3-positive cells at submicromolar/low micromolar 
concentrations (Figure 3A and 3C). This observation confirms 
the non-internalizing behaviour of the cyclo(DKP-RGD) ligand. 
The modest cytotoxic activity of conjugate 3b under these 
conditions may be due to a poor internalization leading to drug 
release mediated by lysosomal β-glucuronidase. 
Conclusions 
The design of new conjugates for the selective release of 
therapeutics at the diseased site represents a highly attractive 
pharmacological approach for the future treatment of cancer 
and other indications. However, the modular nature of these 
products requires a fine tuning of their individual components, 
from the ligand to the linker, from the drug to the spacers. In 
this work, we developed a non-internalizing, αvβ3-targeted 
conjugate (compound 3b), capable of releasing the highly 
potent MMAE payload upon extracellular cleavage of a 
glucoronide linker. Conjugate 3b inhibited the proliferation of 
integrin-expressing U87MG and 786-O cancer cells at low 
nanomolar concentrations. These data suggest that 3b may be 
therapeutically active in vivo against solid tumours expressing 
both integrin αvβ3 (required for the conjugate accumulation at 
the tumour site) and extracellular β-glucuronidase (responsible 
for the drug release). From the structural point of view, the 
use of a long and hydrophilic PEG4 spacer, connecting the 
integrin ligand to the linker moiety, was found to be 
fundamental for the overall conjugate efficiency, conceivably 
due to a diminished steric hindrance around the cleavable 
glycosidic bond. Once released from 3b in its active form, 
MMAE can penetrate the tumour cell membrane by passive 
diffusion. According to this mechanism, MMAE and other 
lipophilic drugs (e.g. duocarmycins, maytansinoids) should be 
considered as ideal payloads, rather than more hydrophilic 
agents (MMAF, α-amanitin), as it was recently demonstrated 
for other non-internalizing conjugates.
27
 As future perspective, 
the quantitative biodistribution analysis of the cyclo(DKP-RGD) 
ligand in tumour-bearing mice would unveil the therapeutic 
potential of this class of conjugates. 
Conflicts of interest 
The authors declare no conflict of interest. 
Acknowledgements 
   
  
 
 
We thank the European Commission (Marie Skłodowska-Curie 
ITN MAGICBULLET 642004) for a PhD fellowship (to P.L.R.) and 
financial support. We also gratefully acknowledge Ministero 
dell’Università e della Ricerca (PRIN 2015 project 
20157WW5EH) for financial support. 
 
Notes and references 
1 American Cancer Society. Cancer Facts & Figures 2018. Atlanta: 
American Cancer Society; 2018. 
2 a) T. Lammers, F. Kiessling, W. E. Hennink, G. Storm, J. Control. 
Release 2012, 161, 175; b) N. Krall, J. Scheuermann, D. Neri, 
Angew. Chem. Int. Ed. 2013, 52, 1384. 
3 a) R. V. J. Chari, M. L. Miller, W. C. Widdison, Angew. Chem. 
Int. Ed. 2014, 53, 3796; b) Goetsch, C. Dumontet, N. Corvaïa, 
Nat. Rev. Drug Discovery 2017, 16, 315. 
4 a) M. Srinivasarao, P. S. Low, Chem. Rev. 2017, 117, 12133; b) 
S. Cazzamalli, A. Dal Corso, F. Widmayer, D. Neri, J. Am. Chem. 
Soc. 2018, 140, 1617.  
5 a) F. Loganzo, M. Sung, H P. Gerber, Mol. Cancer Ther. 2016, 
15, 2825; b) S. Agnello, M. Brand, M. F. Chellat, S. Gazzola, R. 
Riedl, Angew. Chem. Int. Ed. DOI: 10.1002/anie.201802416; c) 
R. Raavé, T. H. van Kuppevelt, W. F. Daamen, J. Control. 
Release 2018, 274, 1; d) S. García-Alonso, A. Ocaña, A. 
Pandiella, Cancer Res. 2018, 78, 2159. 
6 H. P. Gerber, P. D. Senter, I. S. Grewal, mAbs 2009, 1, 247. 
7 C. Sazeides, A. Le, Adv. Exp. Med. Biol. 2018, 1063, 149. 
8 a) F. Li, M. Ulrich, M. Jonas, I. J. Stone, G. Linares, X. Zhang, L. 
Westendorf, D. R. Benjamin, C. L. Law, Mol. Cancer Ther. 2017, 
16; 1347; b) A. H. Staudacher, Y. Li, V. Liapis, J. J. Cheng Hou, D. 
Chin, O. Dolezal, T. E. Adams, P. H. van Berkel, M. P. Brown, 
Mol. Cancer Ther. 2019, 18; 335; c) S. Cazzamalli, B. Ziffels, F. 
Widmayer, P. Murer, G. Pellegrini, F. Pretto, S. Wulhfard, D. 
Neri, Clin. Cancer Res. 2018, 24, 3656. 
9 a) F. Li, K. K Emmerton, M. Jonas, X. Zhang, J. B. Miyamoto, J. 
R. Setter, N. D. Nicholas, N. M. Okeley, R. P. Lyon, D. R. 
Benjamin, C. L. Law, Cancer Res. 2016, 76, 2710; b) A. H. 
Staudacher, M. P. Brown, Br. J. Cancer 2017, 117, 1736. 
10 M. Yasunaga, S. Manabe, D. Tarin, Y. Matsumura, 
Bioconjugate Chem. 2011, 22, 1776.  
11 H. Fuchigami, S. Manabe, M. Yasunaga, Y. Matsumura, Sci. 
Rep. 2018, 8, 14211.  
12 a) S. Cazzamalli, A. Dal Corso, D. Neri, Mol. Cancer Ther. 2016, 
15, 2926; b) S. Cazzamalli, B. Ziffels, F. Widmayer, P. Murer, G. 
Pellegrini, F. Pretto, S. Wulhfard, D. Neri, Clin. Cancer Res. 
2018, 24, 3656; c) S. Cazzamalli, E. Figueras, L. Pethő, A. 
Borbély, C. Steinkühler, D. Neri, N. Sewald, ACS Omega. 2018, 
3, 14726.  
13 a) G. J. Bernardes, G. Casi, S. Trussel, I. Hartmann, K. 
Schwager, J. Scheuermann, D. Neri, Angew. Chem. Int. Ed. 
2012, 51, 941; b) E. Perrino, M. Steiner, N. Krall, G. J. 
Bernardes, F. Pretto, G. Casi, D. Neri, Cancer Res. 2014, 74, 
2569; c) R. Gébleux, S. Wulhfard, G. Casi, D. Neri, Mol. Cancer 
Ther. 2015, 14, 2606. 
 
                                                                                                    
 
 
 
 
 
14 a) R. Gébleux, M. Stringhini, R. Casanova, A. Soltermann, D. 
Neri, Int. J. Cancer 2017, 140, 1670; b) A. Dal Corso, S. 
Cazzamalli, R. Gébleux, M. Mattarella, D. Neri, Bioconjugate 
Chem. 2017, 28, 1826. 
15 M. Marchini, M. Mingozzi, R. Colombo, I. Guzzetti, L. Belvisi, 
F. Vasile, D. Potenza, U. Piarulli, D. Arosio, C. Gennari, Chem. 
Eur. J. 2012, 18, 6195.  
16 a) R. Colombo, M. Mingozzi, L. Belvisi, D. Arosio, U. Piarulli, N. 
Carenini, P. Perego, N. Zaffaroni, M. De Cesare, V. Castiglioni, 
E. Scanziani, C. Gennari, J. Med. Chem. 2012, 55, 10460; b) A. 
Dal Corso, M. Caruso, L. Belvisi, D. Arosio, U. Piarulli, C. 
Albanese, F. Gasparri, A. Marsiglio, F. Sola, S. Troiani, B. 
Valsasina, L. Pignataro, D. Donati, C. Gennari, Chem. Eur. J. 
2015, 21, 6921; c) A. R. M. Dias, A. Pina, A. Dal Corso, D. 
Arosio, L. Belvisi, L. Pignataro, M. Caruso, C. Gennari, Chem. 
Eur. J. 2017, 23, 14410; d) A. Pina, A. Dal Corso, M. Caruso, L. 
Belvisi, D. Arosio, S. Zanella, F. Gasparri, C. Albanese, U. Cucchi, 
I. Fraietta, A. Marsiglio, L. Pignataro, D. Donati, C. Gennari, 
ChemistrySelect 2017, 2, 4759; e) L. Bodero, P. L. Rivas, B. 
Korsak, T. Hechler, A. Pahl, C. Müller, D. Arosio, L. Pignataro, C. 
Gennari, U. Piarulli, Beilstein J. Org. Chem. 2018, 14, 407; f) P. 
López Rivas, I. Ranđelović, A. R. M. Dias, A. Pina, D. Arosio, J. 
Tóvári, G. Mező, A. Dal Corso, L. Pignataro, C. Gennari, Eur. J. 
Org. Chem. 2018, 2902. 
17 J. S. Desgrosellier, D. A. Cheresh, Nat. Rev. Cancer 2010, 10, 9. 
18 a) M. H. Lee, J. Y. Kim, J. H. Han, S. Bhuniya, J. L. Sessler, C. 
Kang, J. S. Kim, J. Am. Chem. Soc. 2012, 134, 12668; b) M. 
Nahrwold, C. Weiß, T. Bogner, F. Mertink, J. Conradi, B. 
Sammet, R. Palmisano, S. R. Gracia, T. Preuße, N. Sewald, J. 
Med. Chem. 2013, 56, 1853. 
19 A. R. M. Dias, A. Pina, A. Dean, H. G. Lerchen, M. Caruso, F. 
Gasparri, I. Fraietta, S. Troiani, D. Arosio, L. Belvisi, L. 
Pignataro, A. Dal Corso, C. Gennari, Chem. Eur. J. 2019, 25, 
1696.  
20 a) A. Tolomelli, P. Galletti, M. Baiula, D. Giacomini, Cancers 
2017, 9, 78; b) F. Nardelli, C. Paissoni, G. Quilici, A. Gori, C. 
Traversari, B. Valentinis, A. Sacchi, A. Corti, F. Curnis, M. Ghitti, 
G. Musco, J. Med. Chem. 2018, 61, 7474; c) S. Panzeri, S. 
Zanella, D. Arosio, L. Vahdati, A. Dal Corso, L. Pignataro, M. 
Paolillo, S. Schinelli, L. Belvisi, C. Gennari, U. Piarulli, Chem. Eur. 
J. 2015, 21, 6265. 
 
  
  
 
 
                                                                                                    
 
 
 
 
 
21 Y.-h. Yang, H. Aloysius, D. Inoyama, Y. Chen, L.-q. Hu, Acta 
Pharm. Sin. B 2011, 1, 143. 
22 a) S. C. Jeffrey, J. B. Andreyka, S. X. Bernhardt, K. M. Kissler, T. 
Kline, J. S. Lenox, R. F. Moser, M. T. Nguyen, N. M. Okeley, I. J. 
Stone, X. Zhang, P. D. Senter, Bioconjugate Chem. 2006, 17, 
831; b) R. V. Kolakowski, K. T. Haelsig, K. K. Emmerton, C. I. 
Leiske, J. B. Miyamoto, J. H. Cochran, R. P. Lyon, P. D. Senter, S. 
C. Jeffrey, Angew. Chem. Int. Ed. 2016, 55, 7948; c) P. J. Burke, 
J. Z. Hamilton, S. C. Jeffrey, J. H. Hunter, S. O. Doronina, N. M. 
Okeley, J. B. Miyamoto, M. E. Anderson, I. J. Stone, M. L. 
Ulrich, J. J. Simmons, E. E. McKinney, P. D. Senter, R. P. Lyon, 
Mol. Cancer Ther. 2017, 16, 116.  
23 B. Renoux, F. Raes, T. Legigan, E. Peraudeau, B. Eddhif, P. 
Poinot, I. Tranoy-Opalinski, J. Alsarraf, O. Koniev, S. Kolodych, 
S. Lerondel, A. Le Pape, J. Clarhautad, S. Papot, Chem. Sci. 
2017, 8, 3427.  
24 K. C. Chen, K. Schmuck, L. F. Tietze, S. R. Roffler, Mol. Pharm. 
2013, 10, 1773. 
25 A. Dal Corso, L. Pignataro, L. Belvisi, C. Gennari, Curr. Top. 
Med. Chem. 2016, 16, 314.  
26 S. K. Shaw, C. L. Schreiber, F. M. Roland, P. M. Battles, S. P. 
Brennan, S. J. Padanilam, B. D. Smith, Bioorg. Med. Chem. 
2018, 26, 2085.  
27 A. Dal Corso, R. Gébleux, P. Murer, A. Soltermann, D. Neri, J. 
Control. Release 2017, 264, 211. 
